Drug Profile
Research programme: anti-cancer therapeutics - Magnus Life Science
Alternative Names: Anti-cancer therapeutics - Magnus LifeLatest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Magnus Life Science; University College London
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors; Cell movement inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma; Solid tumours
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for research development in Malignant-melanoma in United Kingdom (PO)
- 28 Mar 2019 No recent reports of development identified for research development in Solid-tumours in United Kingdom (PO)
- 12 Feb 2015 Early research in Malignant melanoma in United Kingdom (PO)